AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$VNDA

Vanda Pharmaceuticals Inc (VNDA) (Q3 2026) Earnings Call Highlights: Revenue Jumps 24%

Vanda Pharmaceuticals reported a 24% revenue increase in Q3 2026, but net loss widened to $133.6M for the first nine months. Hetlios sales declined 21% due to generic competition, and Nereus revenue is expected to be less than $10M for 2026. Cash reserves decreased by $123.4M. The company anticipates FDA decisions on Quimilza and Bisanti in 2027. CEO Mihael Polymeropoulos discussed commercial plans and clinical trial updates during the earnings call.

Original reporting
finance.yahoo.com
Published Nov 1, 2026, 1:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 1, 2026, 1:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Vanda Pharmaceuticals Inc (VNDA) (Q3 2026) Earnings Call Highlights: Revenue Jumps 24% — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$VNDABullishMed
01

Why it matters

The earnings beat may attract buying interest, but the expanded loss and cash burn could limit upside, leading to mixed market reaction.

02

Market read

The earnings release provides fresh guidance that could move VNDA and influence biotech sector sentiment.

03

What to watch

Potential delays in Quimilza and Basanti launches and competitive pressure on Hetlios may weigh on future performance.

Relevance 7/10Novelty 7/10Timing: post‑earnings today

Background

Vanda Pharmaceuticals held its Q3 2026 earnings call, reporting a 24% revenue increase and providing updates on its pipeline and cash position.

Company-level read

Ticker impact

$VNDABullishHigh confidence
Context

Q3 2026 revenue rose 24% and the company provided guidance on upcoming product launches and cash burn.

Expected impact

potential modest upside as investors price in revenue growth, offset by loss and cash concerns

Evidence & confidence

Strong top‑line beat suggests demand, yet expanding loss and cash depletion could limit rally.

Market effects

Sector

Biotech sector may see modest uplift from Vanda's revenue beat, but cash‑burn concerns could dampen broader sentiment.

Regional

U.S. biotech investors may adjust exposure; limited impact outside North America.

Global

Limited to U.S. biotech and specialty pharma investors.

Counterpoint

What could challenge this read

The widening net loss and cash burn could signal deeper operational issues, suggesting a short‑term pullback.

Key entities

  • Company
    Vanda Pharmaceuticals

    Biopharmaceutical company developing treatments for CNS and immunology disorders.

  • Executive
    Mihael Polymeropoulos

    CEO of Vanda Pharmaceuticals, provided guidance on product launches.

Read at source← All news

StoryVanda Pharmaceuticals posts Q3 2026 revenue up 24% and raises full‑year guidance above $240 M

Also covered by

4 outlets

Related articles

$VNDAMed

H.C. Wainwright reiterates Buy on Vanda stock, cites sales growth

H.C. Wainwright reiterated a Buy rating and $20.00 price target on Vanda Pharmaceuticals (VNDA) after its Q3 2026 results. VNDA reported $69.8M in net sales and a $22.6M net loss, with full-year revenue expected to exceed $240M. Fanapt prescriptions rose 25% YoY and 72% QoQ. Bysanti received FDA approval and Nereus showed growth in prescriptions. VNDA beat earnings estimates, with shares up in after-hours trading.

investing.com
$VNDAMed

The HCPFive: Top News for Healthcare Providers from the Week of 10/25

Vanda Pharmaceuticals reported positive phase 3 trial results for tradipitant in preventing GLP-1-induced vomiting, planning an FDA sNDA submission. Eli Lilly's retatrutide outperformed Ozempic in a type 2 diabetes trial. Agios Pharmaceuticals' mitapivat FDA review extended to February 2027. FDA approved Voceryq for recurrent respiratory papillomatosis.

hcplive.com
$VNDAMed

Vanda (VNDA) Q3 2026 Earnings Call Transcript

Vanda Pharmaceuticals (VNDA) reported Q3 2026 earnings, with revenue up 24% YoY to $172.1M for the first nine months, driven by Fanapt's growth and NEREUS launch. Operating expenses decreased 18% QoQ. Key drugs like BYSANTI, Quimilza, and HETLIOZ are in various stages of FDA review and clinical trials. Fanapt saw a 25% increase in prescriptions, while HETLIOZ faced generic competition.

finance.yahoo.com
$VNDAMed

Vanda Pharmaceuticals Q3 Earnings Call Highlights

Vanda Pharmaceuticals reported Q3 sales of $7.7M for PONVORY, up 10% YoY, and $1.6M for NEREUS, up 60% QoQ. The company expects to launch BYSANTI in Q4 2026 and anticipates $240M+ in full-year 2026 revenue. Operating expenses decreased sequentially to $93.3M, while cash balance fell to $140.5M. Vanda plans FDA discussions for NEREUS and HETLIOZ applications.

finance.yahoo.com
$VNDAMed

Vanda: Q3 Earnings Snapshot

Vanda Pharmaceuticals (VNDA) reported a Q3 loss of $22.6M or 37 cents per share, beating analyst estimates of a 72 cents loss. Revenue was $69.8M, exceeding forecasts of $65.9M. The company expects full-year revenue of $240M.

finance.yahoo.com